Ardelyx

Ardelyx, Inc. is a biopharmaceutical company. engages in the research, development and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ardelyx reports strong Q4 earnings, poised for product expansion

Ardelyx's Q4 performance reflects revenue growth, improved financial efficiency, and progress towards expanding its product portfolio.
While facing challenges such as regulatory processes and market competition, Ardelyx's strengths lie in successful product launches and a proactive commercial strategy.
Opportunities for Ardelyx include leveraging positive feedback for XPHOZAH, raising additional funds for growth, and diversifying revenue through new product launches.

Ardelyx reports sales growth, readies XPHOZAH launch amid challenges

Ardelyx showed strong sales growth for IBSRELA and is poised for the XPHOZAH launch
Financially, the company raised significant funds and maintains a healthy cash position
Challenges include managing expenses and improving profitability amidst losses
Opportunities lie in upcoming product launches and optimizing financial operations

Ardelyx reports strong Q2 performance amidst legislative challenges and growth opportunities

Ardelyx's Q2 performance reflects growth in IBSRELA sales and overall revenue, despite incurring a net loss.
The company faces challenges from pending legislation and financial burdens related to XPHOZAH launch preparation.
Opportunities lie in the potential of XPHOZAH launch, market reception of IBSRELA, and addressing legislative impacts.

Ardelyx reports strong Q3 earnings, poised for successful XPHOZAH launch

Ardelyx's Q3 performance reflects financial strength and positive market reception for IBSRELA.
Challenges in pricing strategy and market competition require strategic planning for XPHOZAH's launch.
Opportunities lie in leveraging financial stability, physician interest, and promotional activities for XPHOZAH success.
The company's commitment to patient access and learnings from IBSRELA will drive future growth and market penetration.

Ardelyx reports strong revenue growth driven by IBSRELA success

Ardelyx is strategically investing in growth, focusing on sustaining momentum for its products. The company is well-resourced and optimistic about the future performance of IBSRELA and XPHOZAH. Despite challenges in operating expenses, Ardelyx remains committed to its commercialization efforts.

Ardelyx reports robust Q1 performance driven by XPHOZAH success

Ardelyx's Q1 2024 earnings call showcased strong revenue growth, particularly driven by XPHOZAH and IBSRELA. The company's cash position remains healthy, and there is a clear focus on expanding market reach and driving adoption of key therapies.

Ardelyx reports robust Q2 earnings, focuses on patient access advocacy

Ardelyx's Q2 2024 performance reflects strong revenue growth driven by IBSRELA and XPHOZAH, with a focus on shareholder value and patient access advocacy. While facing challenges in legal battles and expense management, the company is poised to capitalize on opportunities through sales force expansion and market differentiation strategies.

Ardelyx (ARDX) reports robust Q3 earnings, navigates Medicare coverage challenges

Ardelyx's Q3 earnings call highlighted strong financial performance, success of key medications, and strategies to address Medicare coverage challenges. The company's focus on patient access, commitment to therapy availability, and positive market impact showcase its growth potential and resilience in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx has only one approved therapy, IBS drug Isbrela. The company saw improved second-quarter financials but is not yet profitable.

Why Shares of Ardelyx Were Down Wednesday

Ardelyx shows strong financial health, underpinned by 61% QoQ growth in flagship product Ibsrela and an 18-month cash runway. Japanese approval of tenapanor is a pivotal catalyst, targeting unmet needs in CKD-related hyperphosphatemia and fortifying its U.S. FDA approval prospects. Upgrade Ardelyx to "Buy" given its robust balance sheet, diversified drug portfolio targeting high unmet clinical needs, and indicators of an inflection point.

Rising Sun Over Ardelyx: A Tenapanor Tale (Rating Upgrade)

WALTHAM, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the publication of results from the T3MPO-3 long-term open-label safety trial of IBSRELA® (tenapanor) for irritable bowel syndrome with constipation (IBS-C) in the Journal of Neurogastroenterology and Motility (JNM). The paper, titled “Long-term safety of tenapanor in patients with irritable bowel syndrome with constipation in the T3MPO-3 study,” can be accessed in the current online edition of the publication. IBSRELA, discovered and developed by Ardelyx, has a first-in-class mechanism of action and is approved by the U.S. Food and Drug Administration to treat IBS-C in adults.

Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility

Ardelyx Inc. shares ARDX, +7.92% gained 6% premarket on Monday after the company announced that its partner Kyowa Kirin Co. Ltd. received Japanese regulatory approval for tenapanor for patients with chronic kidney disease on dialysis.

Ardelyx shares climb as kidney-disease drug gets green light from Japanese regulators

Approval announced by Kyowa Kirin, Ardelyx Collaboration Partner Ardelyx to receive $30 million from Kyowa Kirin in milestone and license amendment payments and $5 million from HealthCare Royalty Partners under a Financing Agreement WALTHAM, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) --  Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that its collaboration partner in Japan, Kyowa Kirin Co., Ltd.

Tenapanor for Hyperphosphatemia Approved in Japan

Canaan Inc.

Savara

A new month arrives and with it comes new investment opportunities. We will not always need such a large capital to make our investments, for these penny stocks present us with good opportunities that we can take advantage of, with little capital but perhaps with great returns.

The 3 Best Penny Stocks to Buy Now: September 2023

The RealReal

T2 Biosystems

Wheels Up Experience

When it comes to stock trading, penny stocks stand out, captivating many with the promise of substantial returns. These stocks, often priced under $5 per share, belong to smaller companies and typically don't trade on the major stock exchanges.

Best Penny Stocks To Buy Now? 4 To Watch Before Labor Day

EVgo

Tilray Brands

There's a certain allure in the world of penny stocks. For savvy investors, the promise of top penny stock picks is too enticing to resist, especially when you can scoop up several shares with a $100 bill.

The 3 Most Promising Penny Stocks to Own Now

Nordic American Tankers

The sell-off in the broader stock indexes such as the S&P 500 and the Nasdaq has led to the rise of penny stocks to buy. True, it's tempting to buy high-performing momentum stocks.

3 Penny Stocks You'll Regret Not Buying Soon

Rocket Lab USA

SoundHound AI Inc

United States productivity increased by a 3.7% annualized rate in Q2 2023. Michael Feroli, Chief U.S. economist at JPMorgan (NYSE: JPM ), wrote that expectations for a strong boost in the three-month period “offer glimmers of hope that trend productivity is picking up,” as rising investment in software and information processing will boost growth for the economy.

Don't Sleep on These 3 Penny Stocks That Will Mint Millionaires

Opendoor

Virgin Galactic

Vroom

If you're trying to find the best penny stocks to buy now, you're not alone. There are plenty of reasons that support trading in these cheap stocks.

Best Penny Stocks To Buy Now? 4 Under $5 To Watch

Bioline RX

Phathom Pharmaceuticals

One of the safest sectors on the market is biotech. After all, we can't stop people from aging — at least not yet.

3 Cheap Biotech Stocks That Smart Investors Will Snap Up Now

Karyopharm Therapeutics

TRACON Pharmaceuticals

In a stock market characterized by growing unpredictability, traders are leaning on every possible resource. One such indispensable tool, whether dealing with penny stocks or more expensive shares, is the insight provided by analysts.

Penny Stocks To Buy Now? 3 With Ratings Up To 1,742%

CM Life Sciences III

Rite Aid

Penny stocks are an interesting asset class. On any given day, you will see at least a handful experiencing extreme levels and explosive moves.

Best Penny Stocks To Watch After Fitch Downgrade? 3 For Your List

Continued successful launch of IBSRELA, with Q 2 net sales revenue of $18.3 million ; Company currently expects 2023 full year IBSRELA net sales revenue to be $72 to $77 million

Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance

Apple

Amgen

Celsius Holdings

Coinbase

Cisco Systems

Chevron

DocGo

Diamond Offshore Drilling Inc

New Oriental Education & Technology Group

e.l.f. Beauty

Enphase Energy

Evolution Petroleum

Fluence Energy

FTC Solar

Genius Sports

GSX Techedu Inc.

Immunocore Holdings

Intel

Inter & Co Inc

JPMorgan Chase & Co

Coca-Cola

MoonLake Immunotherapeutics

Microsoft

Noble Corp PLC

Two new Breakout Stocks for Week 31 curated by the MDA model for 10% short-term upside and additional model selections. This week two of four picks gained over 10% in less than a week with peak gains in CLLS +16.8% AUTL+15.5% but the portfolio failed to hold gains. The streak of weekly picks gaining over 10% in less than a week has increased to 255 out of 322 trading weeks (79.2%) not including multiple gainers or warning signals.

August MDA Breakout Stocks Week 31 - 2023: High-Frequency Gainers To Give You An Edge

Akari Therapeutics

Carmell Therapeutics Corp

Homology Medicines

Invitae

Rigetti Computing

Penny stocks hold a distinctive charm for many investors. Amidst fluctuating market trends and the occasional downturn, there's often a group of these low-cost stocks surging in value.

Best Penny Stocks To Buy? 6 To Watch Before Next Week

WALTHAM, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Wednesday, August 2, 2023, at 8:00 a.m.

Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023

WALTHAM, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, president and chief executive officer of Ardelyx, will present on behalf of the company at the virtual H.C. Wainwright 2nd Annual Kidney Conference on Tuesday, July 25, 2023 at 2:00 P.M. Eastern Time.

Ardelyx to Present at the H.C. Wainwright 2nd Annual Kidney Conference

Acceptance of NDA Submission triggers as $2 million milestone payment to Ardelyx by Fosun Pharma Acceptance of NDA Submission triggers as $2 million milestone payment to Ardelyx by Fosun Pharma

Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China

Abeona Therapeutics

Windtree Therapeutics

Penny stocks often represent an intriguing opportunity for investors. Defined by the U.S. Securities and Exchange Commission as shares trading for less than $5, these stocks generally belong to small companies that may not yet have made their mark in the mainstream market.

3 Penny Stocks To Watch Before Next Week; Time To Buy?

WALTHAM, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 7, 2023, at 8:30 a.m. ET in New York City.

Ardelyx to Present at the Jefferies 2023 Healthcare Conference

The regulatory date for potential blockbuster XPHOZAH was set for October. If the Market was disappointed by a perceived delay, it shouldn't have been.

Ardelyx: Final Countdown Begins

WALTHAM, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmission of a New Drug Application (NDA) for XPHOZAH® (tenapanor) for the control of serum phosphate in adult patients with chronic kidney disease on dialysis who have had an inadequate response or intolerance to a phosphate binder therapy.

Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)

Cue Biopharma

Precigen

Sana Biotechnology

Atossa Genetics

Corvus Pharmaceuticals

Most of the biggest biotech stocks on the market started off as unknown penny stocks. Look at Axsome Therapeutics (NASDAQ: AXSM ), for example.

7 High-Potential Penny Stocks in the Biotech Sector

News for Ardelyx Stock (ARDX)